Skip to main content
FDA approves Eli Lilly's migraine drug Reyvow

Eli Lilly and Co.'s Reyvow, or lasmiditan, gained FDA approval for the treatment of acute migraine, giving the company a second drug for treatment of migraine following last year's approval of Emgality, or galcanezumab. The drug will not be available to patients until after Drug Enforcement Administration classification, expected in the next three months.

Full Story: